Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
How to Do Better Research: A Practical Guide for Medical and Community Medicine Researchers
2+ hour, 18+ min ago (1192+ words) From a Good Research Question to Meaningful Evidence By Dr. Shamin Eabenson, MBBS, MD Community …...
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
10+ hour, 53+ min ago (848+ words) Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). In the primary endpoint analysis, Enhertu monotherapy significantly reduced…...
Félix Guerrero-Ramos on Bladder Cancer Advances
1+ week, 2+ day ago (653+ words) EMJ This site is intended for healthcare professionals Félix Guerrero-Ramos on Bladder Cancer Advances Félix Guerrero-Ramos | Oncologic Urology Unit Coordinator, Department of Urology, Hospital Universitario 12 de Octubre, Madrid; Co-founder, Danae Urogenomics, Madrid, Spain What first drew you to uro-oncology and,…...
Noxopharm moves lupus skin therapy toward next human trial
9+ hour, 32+ min ago (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...
Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit
9+ hour, 22+ min ago (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...
Yuhan Corporation Unveils Clinical Trial for Oral HER2-Targeted Therapy...Potential Efficacy for Brain Metastases Expected
9+ hour, 50+ min ago (456+ words) Published 14 Sep.2026 13:41(KST) Yuhan Corporation has disclosed the clinical phase 1/2 trial design and the current progress for its oral HER2-targeted therapy candidate, YH42946. The company plans to secure initial clinical results by the end of this year, determine the recommended dose,…...
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
10+ hour, 53+ min ago (484+ words) Definium Therapeutics to Discuss Topline Results from Phase 3 Pan The National Law Review Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK--(BUSINESS WIRE)…...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
10+ hour, 53+ min ago (1000+ words) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on…...
TAGRISSO?? (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
10+ hour, 9+ min ago (605+ words) Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages These results were presented today during the Presidential…...
A study of ayahuasca users found a mental health pattern researchers cannot yet explain
10+ hour, 32+ min ago (705+ words) Researchers compared first-time and experienced ayahuasca users to see how prior exposure relates to mood, stress, spirituality, substance use, and beliefs about consciousness. Close-up of Banisteriopsis Caapi vines, one of the Ayahuasca plants. Study: Prior ayahuasca experience is associated with…...